



Case Report

Diabetes Could Be a Warning Sign of Pancreatic Cancer: A Case Report and Literature Review

Nassima Dekdouk^{*}, Radia Yala, Sofiane Hamma, Salim Daoud, Charafa Bouderies, Djamil Azzouz, Rachid Belhadj

Department of Forensic and Penitentiary Medicine, Faculty of Medicine, Benyoucef Benkhedda University, Algiers, Algeria

Email address:

ness.popouna@gmail.com (N. Dekdouk)

^{*}Corresponding author

To cite this article:

Nassima Dekdouk, Radia Yala, Sofiane Hamma, Salim Daoud, Charafa Bouderies, Djamil Azzouz, Rachid Belhadj. Diabetes Could Be a Warning Sign of Pancreatic Cancer: A Case Report and Literature Review. *International Journal of Gastroenterology*.

Vol. 4, No. 1, 2020, pp. 7-10. doi: 10.11648/j.ijg.20200401.12

Received: December 13, 2019; **Accepted:** January 2, 2020; **Published:** January 16, 2020

Abstract: Pancreatic cancer (PC) is 1 of the deadliest cancers, representing the fourth leading cause of cancer death in the world; This high mortality is due to late symptom onset and because most of the cases of pancreatic cancer are stage IV at diagnosis, and hence not a candidate for curative resection. The following report will serve to emphasize the role of new-onset diabetes in certain patients as a warning sign necessitating further investigation for pancreatic cancer. It's about a 46-years old man was admitted in hospital «service of forensic and penitentiary medicine» for jaundice associated with progressive asthenia, abdominal pain, and weight loss. He had been diagnosed with diabetes 4 weeks earlier by his GP. Despite lifestyle changes, he had been commenced on metformin after just 2 weeks due to poor glycaemic control. Physical examination showed a mass of the upper right quadrant on palpation. Computed tomography of the abdomen showing a solid mass of 55 mm in the head of the pancreas, hypodense in particular, with mild Wirsung and bile ducts dilatation, and the focal thrombi is found at the level of the 9 mm splenomesaraic confluent, with hepatic secondary localization images. He was subsequently diagnosed with new-onset diabetes and metastatic pancreatic cancer. The treatment with basal insulin / bolus and anticoagulant therapy was instituted and after stabilization; the patient has been oriented for bilio-pancreatic derivation, and eventual biopsy in a specialized center, but unfortunately the patient died only a few weeks after. PC occurs with increased frequency in patients with type 2 diabetes mellitus (DM2) which is considered the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity. Although numerous studies have linked both entities since 1833 the mechanism behind this association are complex and not well understood by the moment.

Keywords: Diabetes, Pancreatic Cancer, Diagnosis, Warning Sign

1. Introduction

Pancreatic cancer is one of the most common cancers world-wide, with a 5-year survival rate of approximately [7%-8%], and for most patients, death occurs within 6 months after the diagnosis [1-4].

Despite decades of effort, there are still few early detection methods or effective treatments, and at diagnosis, most patients have locally advanced unresectable or metastatic lesions, rendering them Incurable, [5] PC is expected to become the second leading cause of cancer mortality by 2020

[2].

Diabetes is a multi-factorial and heterogeneous disease, which involves about 424 million people globally according to the latest statistics released by the International Diabetes Federation, this figure being expected to rise to 552 million by 2030 [6, 7].

Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity [2, 8-10].

The association between diabetes mellitus (DM) and pancreatic cancer has been known for over a century; This

association was supported by statistically significant relative risk near to 2 in several studies [11].

It is now well understood that while long-standing diabetes is an etiologic factor for pancreatic cancer, new-onset diabetes can be a manifestation of the cancer [12].

2. Materials and Methods

2.1. Illustrative Case Report

Case report

A 46-years old man was admitted in hospital «service of forensic and penitentiary medicine » for jaundice associated with progressive asthenia, abdominal pain, and weight loss. He had been diagnosed with diabetes 4 weeks earlier by his GP. Despite lifestyle changes, he had been commenced on metformin after just 2 weeks due to poor glycaemic control.

He was a smoker with a 15 pack-year and drank excessive amount of alcohol, weaned for a few years. Her family history was significant for type 2 diabetes and hypertension, but he denied a family history of any cancers.

Physical examination showed: weight, 63.0 kg; height, 168 cm; body mass index, 22 kg/m²; and blood pressure, 130/70 mmHg. His aspecific symptoms, such as weakness and weight loss was thought to be the consequences of diabetes. A mass of the upper right quadrant on palpation.

Laboratory Values:

Hemogram showed level of hemoglobin at 10.09 g/dl, with MCV at 81.8 fland MCHC at 32.5 g/dl; (total leukocytes, 10,000 / mm³, and the level of platelets at 481 x 10⁹/l. The erythrocyte sedimentation rate (ESR) was at 40 mm/hr, a C-reactive protein within the normal range, an elevated lactate dehydrogenase of 455 U/L (normal range, 120 to 240 U/L), and a serum calcium of 7.2 mg/dL. Renal function tests were normal (serum creatinine, 0.7 mg/dL; creatinine clearance, 102 mL/min). electrolytes showed a potassium of 4.3mmol/L, with a sodium of 138 mmol/L Total serum protein and albumin were decreased (5.53 g/dL and 2.36 g/dL). Total cholesterol was approximately at 250 mg/dL. The serum albumin was at 18 g/l [normal range (NR) 35-50]. Livers tests showed alkaline phosphatase at 207IU/l (NR 30-300), alanine aminotransferase (ALT) at 126 IU/l (NR 5-35), aspartate aminotransferase (AST) at 308 IU/l (NR 5-35), gamma-glutamyltranspeptidase (γGT) at 134 IU/l (NR 11-51), phosphatase alkaline [PAL] 609 UI/L [inf 125], total bilirubin 243.4 mg/l [0-11], direct bilirubin 116.87 mg/l [0-2.5], indirect bilirubin 126.53 mg/l [0-8.5], postprandial plasma glucose level was 430 mg/dL; HBA1C8.8 / (4.7–6.3%), TP97.7/, TCK 21.1 sec.

Total cholesterol at 5.9 mmol/l (NR 3.6-5.2), triglycerides at 3.5 mmol/l (NR 0.4-1.5) and normal coagulation profile; viral hepatitis serology was negative. Serum iron at 54 μmol/l (50-175); lipase 23.2 UI/L, Amylase 5UI/ L, are normals.

Hepatitis B antigen and hepatitis C antibody (third-generation) tests were negative.

Urinalysis showed trace amounts of glucose, normal urobilinogen, no protein or ketones, and pH 6.

Computed tomography of the abdomen showing a solid mass of 55 mm in the head of the pancreas, hypodense in particular, with mild Wirsung and bile ducts dilatation, and the focal thrombi is found at the level of the 9 mm splenomersaraic confluent (tr) with hepatic secondary localization images (figure 1).




Figure 1. Computed tomography of the abdomen showing a solid mass of 55 mm (TM) in the head of the pancreas, hypodense in particular; focal thrombi is found at the level of the 9 mm splenomersaraic confluent (tr) with hepatic secondary localization images (M).

2.2. Management and Out-come

The treatment with basal insulin / bolus and anticoagulant therapy (Tinzaparin) was instituted and after stabilization; the patient has been oriented for bilio-pancreatic derivation. And eventual biopsy in a specialized center, but unfortunately the patient died only a few weeks after.

3. Discussion

Pancreatic cancer and diabetes have a complex bidirectional relationship (figure 2). A large proportion (varied between 50%–80% by studies) of pancreatic cancer patients have concurrent diabetes or impaired glucose tolerance [6, 8, 9, 12-19], Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients.

There have been numerous epidemiologic studies, both cohort and case-control, on the association between diabetes and pancreatic cancer. The studies have stratified the risk of cancer based on duration of diabetes. As is to be expected, a number of meta-analyses of these studies have been published (Everhart, Huxley Ben) [14]. The latest meta-analysis, in 2018 by *Ji-Jun Zhang et al*, includes 26 case-control studies published before October 2017 [1].

The early symptoms of pancreatic cancer, such as abdominal pain, weight loss, fatigue, jaundice, and nausea [2, 12, 20], are non specific and may occur late in the course of the disease.

It must be kept in mind that, although rare, PC might be the precipitating factor in diabetic keto-acidosis cases [21, 22].

As a result, pancreatic cancer is usually diagnosed at an advanced stage, frequently after the tumor has already metastasized [5, 15].

Both diabetes and cancer share a dramatic negative impact on both the expectancy and quality of life, and their parallel increase in rate of incidence has stimulated the scientific community to look for a relationship in terms of pathophysiological mechanisms and/or common environment.

In 1957s, the pathologist E. T. Bell reported that patients

suffering by glycosuria and hyperglycemia have an increased incidence of pancreatic carcinoma [7].

The mechanism of the association between DM and PC is mysterious but most hypothesized mechanisms underlying the association between T2DM and PC include hyperinsulinemia, insulin resistance (IR), elevated levels of circulating insulin-like growth factors (IGFs), hyperglycemia and chronic inflammation that influences tumor growth [6, 7, 23].

a) Hyperinsulinemia and insulin resistance

Insulin itself is a growth promoting hormone with mitogenic (but not mutagenic) effects and diabetes associated cancer cells express insulin and IGF-1 receptors which play a key role in cell growth and differentiation [6].

As previously stated, DM2 is a consequence of a deficiency of functional insulin. This deficiency can be due to a lack of production or lack of end-organ response to insulin. In 2004, Chari and colleagues [22] showed that DM2 associated with PC is likely due to both decline in β -cell function and increased end-organ resistance [9].

b) Insulin-like growth factor axis

Peripheral insulin resistance and hyperinsulinemia have been suggested to promote growth in pancreatic cancer cells. Insulin binds to the IGF1 (insulin-like growth factor 1) receptor and thereby increases the amount of available IGF1 (insulin-like growth factor binding protein 1), which in turn stimulates growth in exocrine PaC cells in an autocrine manner [24]. These receptors can stimulate cancer cell proliferation and survival and promote metastasis, thus favoring cancer progression [6, 7].

c) Hyperglycemia

Hyperglycaemia has been found to enhance proliferation, local invasiveness and metastatic potential in pancreatic cancer [23].

Moreover, hyperglycemia is responsible for induction of oxidative stress and DNA damage, which may trigger the first phases of tumorigenesis [7, 14].

Specifically the tumor within the pancreatic parenchyma, is more aggressive in a microenvironment combining hypoxia with hyperglycemia. High glucose levels can up-regulate HIF-1 α expression, which promotes metastasis of pancreatic [24]. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer in a hypoxic environment, pancreatic cancer cells express high levels of the hypoxia-inducible factor 1 α (HIF-1 α) [25].

d) Chronic inflammation

Inflammatory cytokines, ROS, and mediators of inflammatory pathways, such as cyclooxygenase-2 (COX2) and nuclear factor kappa B (NF κ B) are associated with oncogene expression, silencing of tumor suppressor genes, and affect the cell cycle, all of which may facilitate pancreatic carcinogenesis [6].

Increased circulating levels of specific adipose tissue-derived cytokines have been reported to promote tumor cell growth (tumor necrosis factor- α [TNF- α], interleukin [IL]-6), enhance metastasis (TNF- α , IL-6, transforming growth factor [TGF]- β), increase angiogenesis (TNF- α , IL-17, TGF- β), and impair the function of macrophages and NK cells

[7, 24].

Oxidative stress is another player tightly linked with inflammation and cancer risk in diabetes. The levels of all biomarkers of oxidative stress are usually increased in patients with diabetes, and oxidative stress can mediate damage to cell structures, including lipids and membranes, proteins, and especially DNA [7].

Type 2 diabetes or intratumoural leukocyte (macrophage, neutrophil or eosinophil) infiltration alone did not significantly influence pancreatic cancer prognosis. However, among cancer patients with T2D high macrophage or neutrophil tumour-infiltration was associated with a significant reduction in overall survival (adjusted hazard ratio [HR] 7.2; 95% CI 1.5e35.0 and HR 5.4; 95% CI 1.1e26.3, respectively) [3].




Figure 2. The relationship of diabetes and PC. Longstanding diabetes (defined as being present for 3 or more years) is a risk factor for the development of diabetes. PC increases the risk of new-onset diabetes (variably defined as less than 1-3 years) as well as sudden deterioration of chronic, stable diabetes. [2].

4. Conclusion

The prognosis of pancreatic cancer is quite poor and the case illustration underscore PC's aggressive. Nature and the need for early detection. Currently, there are no validated means of screening for PC. Patients presenting with symptoms of PC, which are usually vague and non specific.

References

- [1] J.-J. Zhang, et al. Diabetes mellitus and risk of pancreatic cancer in China: A meta-analysis based on 26 case-control studies, *Prim. Care Diab.* (2018), <https://doi.org/10.1016/j.pcd.2018.11.015>.
- [2] Tammy W. Lo, MSN, ACNP-BC. Screening for Pan in Individuals With Diabetes Mellitus. *The Journal for Nurse Practitioners – JNP*, 2018; 14 (9): 657-662.
- [3] Karnevi E, et al., Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancerpatients with type 2 diabetes, *Pancreatology* (2017), <https://doi.org/10.1016/j.pan.2017.11.003>.
- [4] Asmaa A. Salem, Gerardo G. Mackenzie, Pancreatic cancer: A critical review of dietary risk, *Nutrition Research* 52 (2018) 1–13.
- [5] Zhang ZJ, Qin WJ, Sun YL, Contribution of Biomarkers for Pancreatic Cancer-Associated New-Onset Diabetes to Pancreatic Cancer Screening, *Pathology-Research and Practice* (2018), <https://doi.org/10.1016/j.prp.2018.10.003>.

- [6] Biadgo B and Abebe M. Association between Type 2 DM and Pancreatic Carcinogenesis, The Korean Journal of Gastroenterology, Vol. 67 No. 4, April 2016.
- [7] A. Cignarelli, V. Annamaria Genchi, I. Caruso, A. Natalicchio, S. Perrini, L. Laviola, F. Giorgino, Diabetes and cancer: pathophysiological fundamentals of a 'dangerous affair', Diabetes Research and Clinical Practice (2018), doi: <https://doi.org/10.1016/j.diabres.2018.04.002>.
- [8] Donghui Li, Diabetes and Pancreatic Cancer, Mol Carcinog. 2012 January; 51 (1): 64–74. doi: 10.1002/mc.20771.
- [9] McAuliffe & Christein, Type 2 Diabetes Mellitus and Pancreatic Cancer, Surg Clin N Am 93 (2013) 619–627.
- [10] Zheng Z, et al. Risk Factors for Pancreatic Cancer in China: A Multicenter Case-Control Study, J Epidemiol 2016.
- [11] C. Sacerdote, F. Ricceri, Epidemiological dimensions of the association between type 2 diabetes and cancer: a review of observational Studies. Diabetes Research and Clinical Practice (2018), doi: <https://doi.org/10.1016/j.diabres.2018.03.002>.
- [12] G. Aggarwal et al. New-onset diabetes in pancreatic cancer: A study in the primary care setting. Pancreatology 12 (2012) 156e161.
- [13] Donghui Li and Yixiang Mao. Diabetes as a Risk Factor of Pancreatic Cancer. Pancreapedia: Exocrine Pancreas Knowledge Base Version 1.0, January 14, 2015 [DOI: 10.3998/panc.2015.2].
- [14] T. MUNIRAJ and S. T. CHARI. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012 December; 58 (4): 331–345.
- [15] Feng Wang, Margery Herrington, Jörgen Larsson and Johan Permer. The relationship between diabetes and pancreatic cancer. Molecular Cancer 2003, 2, <http://www.molecular-cancer.com/content/2/1/4>.
- [16] Caroline Sharratt, Varadarajan Baskar. Diabetes as a presenting feature of pancreatic cancer: A case report. Diabetes & Primary Care Vol 11 No 4 2009.
- [17] Morales-Oyarvide V, et al., Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma, Pancreatology (2017), <http://dx.doi.org/10.1016/j.pan.2017.08.073>.
- [18] De Souza et al. Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. JOP. 2016 March; 17 (2): 144–148.
- [19] Rahul Pannala, Ananda Basu, Gloria M Petersen, Suresh T Chari. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009; 10: 88–95.
- [20] Slim et al. Diabetes mellitus as an early symptom of pancreatic cancer diagnosed three years later Annales d' Endocrinologie 70 (2009) 76–79.
- [21] Kaya T, et al., Diabetic ketoacidosis as the presenting manifestation of pancreatic adenocarcinoma with cystic features, Turkish Journal of Emergency Medicine (2016), <http://dx.doi.org/10.1016/j.tjem.2016.05.00>.
- [22] Danny Markabawi, Divya Kondapi, Vikrant T ambe, Rahul Seth, When it is not just DKA; diabetic ketoacidosis as a first presentation of pancreatic adenocarcinoma. Yajem (2017), doi: 10.1016/j.ajem.2018.05.070.
- [23] T. Salvatore, et al., Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist, International Journal of Surgery (2015), <http://dx.doi.org/10.1016/j.ijssu.2015.06.063>.
- [24] A. Bartosch-Härlid R. Andersson. Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease. Pancreatology 2010; 10: 423–428.
- [25] W. Li et al. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Computational and Structural Biotechnology Journal 16 (2018) 479–487.